Topical delgocitinib, a pan-Janus kinase inhibitor, was well tolerated and reduced the severity and symptoms of disease in patients with moderate to severe chronic hand eczema, in two phase 3 trials.
Delgocitinib cream is a topical pan-Janus kinase (JAK) inhibitor. Positive topline results were announced from a second phase 3 study evaluating delgocitinib cream in adult patients with moderate to ...
LAWRENCEVILLE, N.J.--(BUSINESS WIRE)--Asana BioSciences, a clinical stage biopharmaceutical company, announced that it will present additional positive results from a Phase 2b study evaluating the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results